NCT07497269

Brief Summary

The aim of this study is to prospectively evaluate the effects of pulsed and conventional radiofrequency ablation of the ganglion impar on pain, quality of life, and sleep quality in patients with refractory coccydynia, and to determine whether one treatment is superior to the other.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
22mo left

Started Apr 2026

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress7%
Apr 2026Apr 2028

First Submitted

Initial submission to the registry

March 19, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 27, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2028

Last Updated

March 27, 2026

Status Verified

March 1, 2026

Enrollment Period

1 year

First QC Date

March 19, 2026

Last Update Submit

March 24, 2026

Conditions

Keywords

Radiofrequency Ablationlow back painquality of lifecoccyx

Outcome Measures

Primary Outcomes (1)

  • The Numeric Rating Scale (NRS)

    Pain intensity was assessed using the Numeric Rating Scale (NRS), a linear pain scale ranging from 0 (no pain) to 10 (the worst imaginable pain)."

    From enrollment to the end of treatment at 12th months

Secondary Outcomes (3)

  • Oswestry Disability Index (ODI)

    From enrollment to the end of treatment at 12th months

  • Pittsburgh Sleep Quality Index (PSQI)

    From enrollment to the end of treatment at 12 months

  • Global Perceived Effect (GPE)

    From enrollment to the end of treatment at 12th months

Study Arms (2)

Pulse RF Group

ACTIVE COMPARATOR

Radiofrequency ablation is performed on the ganglion impar using a 22G needle with a 10 mm active tip. Tissue impedance and motor/sensory responses are checked before ablation. Pulsed RFA is applied at 42 °C for 4 minutes. Pulsed RF treatments will be applied to patients only once, and pain, disability, sleep quality, and patient satisfaction will be assessed before treatment and at 1, 3, 6, and 12 months after the procedure

Procedure: Pulsed Radiofrequency

Conventional RF Group

ACTIVE COMPARATOR

Conventional RF treatments will be applied to patients only once, and pain, disability, sleep quality, and patient satisfaction will be assessed before treatment and at 1, 3, 6, and 12 months after the procedure Radiofrequency ablation is performed on the ganglion impar using a 22G needle with a 10 mm active tip. Tissue impedance and motor/sensory responses are checked before ablation. Conventional RFA is applied for two cycles of 90 seconds at 80 °C.

Procedure: Conventional Radiofrequency

Interventions

Once the needle is properly positioned along the sacrococcygeal disc line, 1 mL of radiopaque contrast is injected. The needle placement is confirmed in the lateral fluoroscopic view as a comma-shaped spread in the retroperitoneal space. Radiofrequency interventions on the ganglion impar are performed using a radiofrequency generator. A 22G radiofrequency needle (0.7×98.6 mm) with a 10 mm exposed active tip is used. Before performing the ablation, tissue impedance and motor and sensory responses (motor and sensory stimulation) are checked. The expected tissue impedance is \<500 ohms. Sensory paresthesia at \<1 V and 50 Hz is observed around the sacrococcygeal region. Pulsed RFA is applied at 42 °C for 4 minutes after stimulation.

Pulse RF Group

Once the needle is properly positioned along the sacrococcygeal disc line, 1 mL of radiopaque contrast is injected. The needle placement is confirmed in the lateral fluoroscopic view as a comma-shaped spread in the retroperitoneal space. Radiofrequency interventions on the ganglion impar are performed using a radiofrequency generator. A 22G radiofrequency needle (0.7×98.6 mm) with a 10 mm exposed active tip is used. Before performing the ablation, tissue impedance and motor and sensory responses (motor and sensory stimulation) are checked. The expected tissue impedance is \<500 ohms. Sensory paresthesia at \<1 V and 50 Hz is observed around the sacrococcygeal region. Neuroablation is applied for 2 cycles of 90 seconds at 80 °C.

Conventional RF Group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 80 years.
  • Chronic pain in the coccygeal region lasting longer than 3 months, unresponsive to analgesics, anti-inflammatory drugs, and other conservative treatment methods.
  • Patients scheduled to undergo ganglion impar treatment with either conventional or pulsed radiofrequency ablation (RFA).

You may not qualify if:

  • Incomplete medical records.
  • Loss to follow-up.
  • Technical failure during the block procedure.
  • Local infection, bleeding disorders, allergy to contrast agents, or history of spinal surgery.
  • History of malignancy.
  • Refusal to participate in the study.
  • Diagnosed psychological disorders.
  • Individuals unable to communicate effectively or understand instructions.
  • Age under 18 or over 80 years.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Adana City Training and Research Hospital

Adana, Adana, Turkey (Türkiye)

Location

Tobb Etü Hospital

Ankara, Ankara, Turkey (Türkiye)

Location

Related Publications (1)

  • 1-Adas, C., Ozdemir, U., Toman, H., Luleci, N., Luleci, E., & Adas, H. (2016). Transsacrococcygeal approach to ganglion impar: radiofrequency application for the treatment of chronic intractable coccydynia. Journal of pain research, 1173-1177. 2-Romanukha, D. M., & Biloshytsky, V. V. (2024). Minimally Invasive Interventions on Ganglion Impar in Treatment of Patients with Coccygodynia. Ukr Neurosurg J, 1, 43-52. 3-Nasiri, A., Vajari, F. F., Sane, S., & Afsargharehbagh, R. (2024). Assessment of ganglion impar block effect on treatment results of coccydynia: a cross-sectional study. Anesthesiology and Pain Medicine, 14(2), e142137. 4-Turchan, A., Fahmi, A., & Subianto, H. (2018). Impar ganglion block with combination of neurolysis drugs and radiofrequency thermocoagulation for perineal pain. Asian Journal of Neurosurgery, 13(03), 838-841. 5-Gupta, M., & Das, G. (2020). Ganglion Impar block and neurolysis for chronic pain: A review. Journal on Musculoskeletal Ultrasound and Pain Medicine, 6(1), 24-28. 6-Usmani H, Dureja GP, Andleeb R, Tauheed N, Asif N. Conventional Radiofrequency Thermocoagulation vs Pulsed Radiofrequency Neuromodulation of Ganglion Impar in Chronic Perineal Pain of Nononcological Origin. Pain Med.2018;19(12):2348-2356. doi:10.1093/pm/pnx244. PMID: 29329442)

    BACKGROUND

MeSH Terms

Conditions

Back PainLow Back Pain

Interventions

Pulsed Radiofrequency Treatment

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRadiofrequency TherapyRehabilitation

Study Officials

  • Derya Bayram, MD

    Adana City Training and Research Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Two groups of patients with coccydynia
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Doctor

Study Record Dates

First Submitted

March 19, 2026

First Posted

March 27, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

April 1, 2028

Last Updated

March 27, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Individual participant data will not be shared to ensure the confidentiality and privacy of the patients, in accordance with ethical approval and local regulations

Locations